APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs for Metabolic Disorders

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Drugs for Metabolic Disorders Industry Growth and Trends Forecast to 2032

22 December 2025106 pages

Choose your research edition.

Industry ResearchDrugs for Metabolic Disorders Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for Metabolic Disorders Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal Drugs for Metabolic Disorders Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for Metabolic Disorders Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for Metabolic Disorders Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Drugs for Metabolic Disorders market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Drugs for Metabolic Disorders is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Drugs for Metabolic Disorders is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Drugs for Metabolic Disorders is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Drugs for Metabolic Disorders include Takeda Pharmaceutical, Novartis, Merck, Astra Zeneca, Metsubishi Tanabe Pharma, LG Life Science, Kythera, KOWA and Fuji yakuhin, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Drugs for Metabolic Disorders market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Drugs for Metabolic Disorders market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Drugs for Metabolic Disorders market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Drugs for Metabolic Disorders.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Drugs for Metabolic Disorders market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Drugs for Metabolic Disorders Market by Company

Takeda Pharmaceutical

Novartis

Merck

Astra Zeneca

Metsubishi Tanabe Pharma

LG Life Science

Kythera

KOWA

Fuji yakuhin

Boehringer Ingelheim

Drugs for Metabolic Disorders Segment by Type

Amino Acid Metabolism Drug

Glycogen Metabolism Disease Drug

Lipid Metabolism Disease Drug

Other

Drugs for Metabolic Disorders Segment by Application

Hospital

Retail Pharmacy

Drugs for Metabolic Disorders Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Metabolic Disorders market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for Metabolic Disorders and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Metabolic Disorders.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Drugs for Metabolic Disorders manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Drugs for Metabolic Disorders in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Amino Acid Metabolism Drug Table 2. Major Company of Glycogen Metabolism Disease Drug Table 3. Major Company of Lipid Metabolism Disease Drug Table 4. Major Company of Other Table 5. Global Drugs for Metabolic Disorders Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global Drugs for Metabolic Disorders Sales by Type (2021-2026) & (k units) Table 7. Global Drugs for Metabolic Disorders Sales Market Share in Volume by Type (2021-2026) Table 8. Global Drugs for Metabolic Disorders Sales by Type (2021-2026) & (US$ Million) Table 9. Global Drugs for Metabolic Disorders Sales Market Share in Value by Type (2021-2026) Table 10. Global Drugs for Metabolic Disorders Price by Type (2021-2026) & (US$/unit) Table 11. Global Drugs for Metabolic Disorders Sales by Type (2027-2032) & (k units) Table 12. Global Drugs for Metabolic Disorders Sales Market Share in Volume by Type (2027-2032) Table 13. Global Drugs for Metabolic Disorders Sales by Type (2027-2032) & (US$ Million) Table 14. Global Drugs for Metabolic Disorders Sales Market Share in Value by Type (2027-2032) Table 15. Global Drugs for Metabolic Disorders Price by Type (2027-2032) & (US$/unit) Table 16. North America Drugs for Metabolic Disorders Sales by Type (2021-2026) & (k units) Table 17. North America Drugs for Metabolic Disorders Sales by Type (2021-2026) & (US$ Million) Table 18. Europe Drugs for Metabolic Disorders Sales by Type (2021-2026) & (k units) Table 19. Europe Drugs for Metabolic Disorders Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific Drugs for Metabolic Disorders Sales by Type (2021-2026) & (k units) Table 21. Asia-Pacific Drugs for Metabolic Disorders Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America Drugs for Metabolic Disorders Sales by Type (2021-2026) & (k units) Table 23. Latin America Drugs for Metabolic Disorders Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa Drugs for Metabolic Disorders Sales by Type (2021-2026) & (k units) Table 25. Middle East and Africa Drugs for Metabolic Disorders Sales by Type (2021-2026) & (US$ Million) Table 26. Drugs for Metabolic Disorders Industry Trends Table 27. Drugs for Metabolic Disorders Industry Drivers Table 28. Drugs for Metabolic Disorders Industry Opportunities and Challenges Table 29. Drugs for Metabolic Disorders Industry Restraints Table 30. Global Drugs for Metabolic Disorders Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global Drugs for Metabolic Disorders Revenue Market Share by Company (2021-2026) Table 32. Global Drugs for Metabolic Disorders Sales by Company (2021-2026) & (k units) Table 33. Global Drugs for Metabolic Disorders Sales Share by Company (2021-2026) Table 34. Global Drugs for Metabolic Disorders Market Price by Company (2021-2026) & (US$/unit) Table 35. Global Drugs for Metabolic Disorders Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global Drugs for Metabolic Disorders Major Company Production Sites and Headquarters Table 37. Global Drugs for Metabolic Disorders Company, Product Type & Application Table 38. Global Drugs for Metabolic Disorders Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global Drugs for Metabolic Disorders by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global Drugs for Metabolic Disorders Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global Drugs for Metabolic Disorders Sales by Region (2021-2026) & (k units) Table 43. Global Drugs for Metabolic Disorders Sales Market Share in Volume by Region (2021-2026) Table 44. Global Drugs for Metabolic Disorders Sales by Region (2021-2026) & (US$ Million) Table 45. Global Drugs for Metabolic Disorders Sales Market Share in Value by Region (2021-2026) Table 46. Global Drugs for Metabolic Disorders Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 47. Global Drugs for Metabolic Disorders Sales by Region (2027-2032) & (k units) Table 48. Global Drugs for Metabolic Disorders Sales Market Share in Volume by Region (2027-2032) Table 49. Global Drugs for Metabolic Disorders Sales by Region (2027-2032) & (US$ Million) Table 50. Global Drugs for Metabolic Disorders Sales Market Share in Value by Region (2027-2032) Table 51. Global Drugs for Metabolic Disorders Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 52. Global Drugs for Metabolic Disorders Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global Drugs for Metabolic Disorders Sales by Application (2021-2026) & (k units) Table 54. Global Drugs for Metabolic Disorders Sales Market Share in Volume by Application (2021-2026) Table 55. Global Drugs for Metabolic Disorders Sales by Application (2021-2026) & (US$ Million) Table 56. Global Drugs for Metabolic Disorders Sales Market Share in Value by Application (2021-2026) Table 57. Global Drugs for Metabolic Disorders Price by Application (2021-2026) & (US$/unit) Table 58. Global Drugs for Metabolic Disorders Sales by Application (2027-2032) & (k units) Table 59. Global Drugs for Metabolic Disorders Sales Market Share in Volume by Application (2027-2032) Table 60. Global Drugs for Metabolic Disorders Sales by Application (2027-2032) & (US$ Million) Table 61. Global Drugs for Metabolic Disorders Sales Market Share in Value by Application (2027-2032) Table 62. Global Drugs for Metabolic Disorders Price by Application (2027-2032) & (US$/unit) Table 63. North America Drugs for Metabolic Disorders Sales by Application (2021-2026) & (k units) Table 64. North America Drugs for Metabolic Disorders Sales by Application (2021-2026) & (US$ Million) Table 65. Europe Drugs for Metabolic Disorders Sales by Application (2021-2026) & (k units) Table 66. Europe Drugs for Metabolic Disorders Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific Drugs for Metabolic Disorders Sales by Application (2021-2026) & (k units) Table 68. Asia-Pacific Drugs for Metabolic Disorders Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America Drugs for Metabolic Disorders Sales by Application (2021-2026) & (k units) Table 70. Latin America Drugs for Metabolic Disorders Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa Drugs for Metabolic Disorders Sales by Application (2021-2026) & (k units) Table 72. Middle East and Africa Drugs for Metabolic Disorders Sales by Application (2021-2026) & (US$ Million) Table 73. Takeda Pharmaceutical Company Information Table 74. Takeda Pharmaceutical Business Overview Table 75. Takeda Pharmaceutical Drugs for Metabolic Disorders Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Takeda Pharmaceutical Drugs for Metabolic Disorders Product Portfolio Table 77. Takeda Pharmaceutical Recent Development Table 78. Novartis Company Information Table 79. Novartis Business Overview Table 80. Novartis Drugs for Metabolic Disorders Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Novartis Drugs for Metabolic Disorders Product Portfolio Table 82. Novartis Recent Development Table 83. Merck Company Information Table 84. Merck Business Overview Table 85. Merck Drugs for Metabolic Disorders Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Merck Drugs for Metabolic Disorders Product Portfolio Table 87. Merck Recent Development Table 88. Astra Zeneca Company Information Table 89. Astra Zeneca Business Overview Table 90. Astra Zeneca Drugs for Metabolic Disorders Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Astra Zeneca Drugs for Metabolic Disorders Product Portfolio Table 92. Astra Zeneca Recent Development Table 93. Metsubishi Tanabe Pharma Company Information Table 94. Metsubishi Tanabe Pharma Business Overview Table 95. Metsubishi Tanabe Pharma Drugs for Metabolic Disorders Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Metsubishi Tanabe Pharma Drugs for Metabolic Disorders Product Portfolio Table 97. Metsubishi Tanabe Pharma Recent Development Table 98. LG Life Science Company Information Table 99. LG Life Science Business Overview Table 100. LG Life Science Drugs for Metabolic Disorders Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. LG Life Science Drugs for Metabolic Disorders Product Portfolio Table 102. LG Life Science Recent Development Table 103. Kythera Company Information Table 104. Kythera Business Overview Table 105. Kythera Drugs for Metabolic Disorders Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Kythera Drugs for Metabolic Disorders Product Portfolio Table 107. Kythera Recent Development Table 108. KOWA Company Information Table 109. KOWA Business Overview Table 110. KOWA Drugs for Metabolic Disorders Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 111. KOWA Drugs for Metabolic Disorders Product Portfolio Table 112. KOWA Recent Development Table 113. Fuji yakuhin Company Information Table 114. Fuji yakuhin Business Overview Table 115. Fuji yakuhin Drugs for Metabolic Disorders Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 116. Fuji yakuhin Drugs for Metabolic Disorders Product Portfolio Table 117. Fuji yakuhin Recent Development Table 118. Boehringer Ingelheim Company Information Table 119. Boehringer Ingelheim Business Overview Table 120. Boehringer Ingelheim Drugs for Metabolic Disorders Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 121. Boehringer Ingelheim Drugs for Metabolic Disorders Product Portfolio Table 122. Boehringer Ingelheim Recent Development Table 123. North America Drugs for Metabolic Disorders Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 124. North America Drugs for Metabolic Disorders Sales by Country (2021-2026) & (k units) Table 125. North America Drugs for Metabolic Disorders Sales Market Share by Country (2021-2026) Table 126. North America Drugs for Metabolic Disorders Sales Forecast by Country (2027-2032) & (k units) Table 127. North America Drugs for Metabolic Disorders Sales Market Share Forecast by Country (2027-2032) Table 128. North America Drugs for Metabolic Disorders Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 129. North America Drugs for Metabolic Disorders Market Size by Country (2021-2026) & (US$ Million) Table 130. North America Drugs for Metabolic Disorders Market Share by Country (2021-2026) Table 131. North America Drugs for Metabolic Disorders Market Size Forecast by Country (2027-2032) & (US$ Million) Table 132. North America Drugs for Metabolic Disorders Market Share Forecast by Country (2027-2032) Table 133. Europe Drugs for Metabolic Disorders Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 134. Europe Drugs for Metabolic Disorders Sales by Country (2021-2026) & (k units) Table 135. Europe Drugs for Metabolic Disorders Sales Market Share by Country (2021-2026) Table 136. Europe Drugs for Metabolic Disorders Sales Forecast by Country (2027-2032) & (k units) Table 137. Europe Drugs for Metabolic Disorders Sales Market Share Forecast by Country (2027-2032) Table 138. Europe Drugs for Metabolic Disorders Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 139. Europe Drugs for Metabolic Disorders Market Size by Country (2021-2026) & (US$ Million) Table 140. Europe Drugs for Metabolic Disorders Market Share by Country (2021-2026) Table 141. Europe Drugs for Metabolic Disorders Market Size Forecast by Country (2027-2032) & (US$ Million) Table 142. Europe Drugs for Metabolic Disorders Market Share Forecast by Country (2027-2032) Table 143. Asia-Pacific Drugs for Metabolic Disorders Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 144. Asia-Pacific Drugs for Metabolic Disorders Sales by Country (2021-2026) & (k units) Table 145. Asia-Pacific Drugs for Metabolic Disorders Sales Market Share by Country (2021-2026) Table 146. Asia-Pacific Drugs for Metabolic Disorders Sales Forecast by Country (2027-2032) & (k units) Table 147. Asia-Pacific Drugs for Metabolic Disorders Sales Market Share Forecast by Country (2027-2032) Table 148. Asia-Pacific Drugs for Metabolic Disorders Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. Asia-Pacific Drugs for Metabolic Disorders Market Size by Country (2021-2026) & (US$ Million) Table 150. Asia-Pacific Drugs for Metabolic Disorders Market Share by Country (2021-2026) Table 151. Asia-Pacific Drugs for Metabolic Disorders Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. Asia-Pacific Drugs for Metabolic Disorders Market Share Forecast by Country (2027-2032) Table 153. Latin America Drugs for Metabolic Disorders Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 154. Latin America Drugs for Metabolic Disorders Sales by Country (2021-2026) & (k units) Table 155. Latin America Drugs for Metabolic Disorders Sales Market Share by Country (2021-2026) Table 156. Latin America Drugs for Metabolic Disorders Sales Forecast by Country (2027-2032) & (k units) Table 157. Latin America Drugs for Metabolic Disorders Sales Market Share Forecast by Country (2027-2032) Table 158. Latin America Drugs for Metabolic Disorders Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. Latin America Drugs for Metabolic Disorders Market Size by Country (2021-2026) & (US$ Million) Table 160. Latin America Drugs for Metabolic Disorders Market Share by Country (2021-2026) Table 161. Latin America Drugs for Metabolic Disorders Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. Latin America Drugs for Metabolic Disorders Market Share Forecast by Country (2027-2032) Table 163. Middle East and Africa Drugs for Metabolic Disorders Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 164. Middle East and Africa Drugs for Metabolic Disorders Sales by Country (2021-2026) & (k units) Table 165. Middle East and Africa Drugs for Metabolic Disorders Sales Market Share by Country (2021-2026) Table 166. Middle East and Africa Drugs for Metabolic Disorders Sales Forecast by Country (2027-2032) & (k units) Table 167. Middle East and Africa Drugs for Metabolic Disorders Sales Market Share Forecast by Country (2027-2032) Table 168. Middle East and Africa Drugs for Metabolic Disorders Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 169. Middle East and Africa Drugs for Metabolic Disorders Market Size by Country (2021-2026) & (US$ Million) Table 170. Middle East and Africa Drugs for Metabolic Disorders Market Share by Country (2021-2026) Table 171. Middle East and Africa Drugs for Metabolic Disorders Market Size Forecast by Country (2027-2032) & (US$ Million) Table 172. Middle East and Africa Drugs for Metabolic Disorders Market Share Forecast by Country (2027-2032) Table 173. Key Raw Materials Table 174. Raw Materials Key Suppliers Table 175. Drugs for Metabolic Disorders Distributors List Table 176. Drugs for Metabolic Disorders Customers List Table 177. Research Programs/Design for This Report Table 178. Authors List of This Report Table 179. Secondary Sources Table 180. Primary Sources List of Figures Figure 1. Drugs for Metabolic Disorders Image Figure 2. Global Drugs for Metabolic Disorders Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs for Metabolic Disorders Market Size (2021-2032) & (US$ Million) Figure 4. Global Drugs for Metabolic Disorders Sales (2021-2032) & (k units) Figure 5. Amino Acid Metabolism Drug Image Figure 6. Global Amino Acid Metabolism Drug Sales YoY Growth (2021-2032) & (k units) Figure 7. Glycogen Metabolism Disease Drug Image Figure 8. Global Glycogen Metabolism Disease Drug Sales YoY Growth (2021-2032) & (k units) Figure 9. Lipid Metabolism Disease Drug Image Figure 10. Global Lipid Metabolism Disease Drug Sales YoY Growth (2021-2032) & (k units) Figure 11. Other Image Figure 12. Global Other Sales YoY Growth (2021-2032) & (k units) Figure 13. Global Drugs for Metabolic Disorders Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global Drugs for Metabolic Disorders Market Share by Type 2025 VS 2032 Figure 15. North America Drugs for Metabolic Disorders Sales Market Share in Volume by Type in 2025 Figure 16. North America Drugs for Metabolic Disorders Sales Market Share in Value by Type in 2025 Figure 17. Europe Drugs for Metabolic Disorders Sales Market Share in Volume by Type in 2025 Figure 18. Europe Drugs for Metabolic Disorders Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific Drugs for Metabolic Disorders Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific Drugs for Metabolic Disorders Sales Market Share in Value by Type in 2025 Figure 21. Latin America Drugs for Metabolic Disorders Sales Market Share in Volume by Type in 2025 Figure 22. Latin America Drugs for Metabolic Disorders Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa Drugs for Metabolic Disorders Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa Drugs for Metabolic Disorders Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 Drugs for Metabolic Disorders Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Hospital Image Figure 28. Global Hospital Sales YoY Growth (2021-2032) & (k units) Figure 29. Retail Pharmacy Image Figure 30. Global Retail Pharmacy Sales YoY Growth (2021-2032) & (k units) Figure 31. Global Drugs for Metabolic Disorders Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Drugs for Metabolic Disorders Market Share by Application 2025 VS 2032 Figure 33. North America Drugs for Metabolic Disorders Sales Market Share in Volume by Application in 2025 Figure 34. North America Drugs for Metabolic Disorders Sales Market Share in Value by Application in 2025 Figure 35. Europe Drugs for Metabolic Disorders Sales Market Share in Volume by Application in 2025 Figure 36. Europe Drugs for Metabolic Disorders Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific Drugs for Metabolic Disorders Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific Drugs for Metabolic Disorders Sales Market Share in Value by Application in 2025 Figure 39. Latin America Drugs for Metabolic Disorders Sales Market Share in Volume by Application in 2025 Figure 40. Latin America Drugs for Metabolic Disorders Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa Drugs for Metabolic Disorders Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa Drugs for Metabolic Disorders Sales Market Share in Value by Application in 2025 Figure 43. North America Drugs for Metabolic Disorders Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 44. North America Drugs for Metabolic Disorders Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America Drugs for Metabolic Disorders Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America Drugs for Metabolic Disorders Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Drugs for Metabolic Disorders Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 48. Europe Drugs for Metabolic Disorders Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Drugs for Metabolic Disorders Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Drugs for Metabolic Disorders Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Drugs for Metabolic Disorders Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 52. Asia-Pacific Drugs for Metabolic Disorders Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Drugs for Metabolic Disorders Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific Drugs for Metabolic Disorders Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Drugs for Metabolic Disorders Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 56. Latin America Drugs for Metabolic Disorders Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Drugs for Metabolic Disorders Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Drugs for Metabolic Disorders Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Drugs for Metabolic Disorders Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 60. Middle East and Africa Drugs for Metabolic Disorders Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Drugs for Metabolic Disorders Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa Drugs for Metabolic Disorders Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Drugs for Metabolic Disorders Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. Drugs for Metabolic Disorders Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Amino Acid Metabolism Drug
  • Glycogen Metabolism Disease Drug
  • Lipid Metabolism Disease Drug
  • Other
Applications
  • Hospital
  • Retail Pharmacy
Companies covered
  • Takeda Pharmaceutical
  • Novartis
  • Merck
  • Astra Zeneca
  • Metsubishi Tanabe Pharma
  • LG Life Science
  • Kythera
  • KOWA
  • Fuji yakuhin
  • Boehringer Ingelheim

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Drugs for Metabolic Disorders Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Drugs for Metabolic Disorders Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Drugs for Metabolic Disorders Market by Type
  6. 1.3.1 Amino Acid Metabolism Drug
  7. 1.3.2 Glycogen Metabolism Disease Drug
  8. 1.3.3 Lipid Metabolism Disease Drug
  9. 1.3.4 Other
  10. 1.4 Global Drugs for Metabolic Disorders Market Size by Type
  11. 1.4.1 Global Drugs for Metabolic Disorders Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global Drugs for Metabolic Disorders Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global Drugs for Metabolic Disorders Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America Drugs for Metabolic Disorders Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe Drugs for Metabolic Disorders Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific Drugs for Metabolic Disorders Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America Drugs for Metabolic Disorders Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa Drugs for Metabolic Disorders Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Drugs for Metabolic Disorders Industry Trends
  2. 2.2 Drugs for Metabolic Disorders Industry Drivers
  3. 2.3 Drugs for Metabolic Disorders Industry Opportunities and Challenges
  4. 2.4 Drugs for Metabolic Disorders Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Drugs for Metabolic Disorders Revenue (2021-2026)
  2. 3.2 Global Top Players by Drugs for Metabolic Disorders Sales (2021-2026)
  3. 3.3 Global Top Players by Drugs for Metabolic Disorders Price (2021-2026)
  4. 3.4 Global Drugs for Metabolic Disorders Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Drugs for Metabolic Disorders Major Company Production Sites & Headquarters
  6. 3.6 Global Drugs for Metabolic Disorders Company, Product Type & Application
  7. 3.7 Global Drugs for Metabolic Disorders Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Drugs for Metabolic Disorders Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Drugs for Metabolic Disorders Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Drugs for Metabolic Disorders Tier 1, Tier 2, and Tier 3
4 Drugs for Metabolic Disorders Regional Status and Outlook
  1. 4.1 Global Drugs for Metabolic Disorders Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Drugs for Metabolic Disorders Historic Market Size by Region
  3. 4.2.1 Global Drugs for Metabolic Disorders Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Drugs for Metabolic Disorders Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Drugs for Metabolic Disorders Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Drugs for Metabolic Disorders Forecasted Market Size by Region
  7. 4.3.1 Global Drugs for Metabolic Disorders Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Drugs for Metabolic Disorders Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Drugs for Metabolic Disorders Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Drugs for Metabolic Disorders by Application
  1. 5.1 Drugs for Metabolic Disorders Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Retail Pharmacy
  4. 5.2 Global Drugs for Metabolic Disorders Market Size by Application
  5. 5.2.1 Global Drugs for Metabolic Disorders Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global Drugs for Metabolic Disorders Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global Drugs for Metabolic Disorders Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America Drugs for Metabolic Disorders Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe Drugs for Metabolic Disorders Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific Drugs for Metabolic Disorders Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America Drugs for Metabolic Disorders Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa Drugs for Metabolic Disorders Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Takeda Pharmaceutical
  2. 6.1.1 Takeda Pharmaceutical Company Information
  3. 6.1.2 Takeda Pharmaceutical Business Overview
  4. 6.1.3 Takeda Pharmaceutical Drugs for Metabolic Disorders Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Takeda Pharmaceutical Drugs for Metabolic Disorders Product Portfolio
  6. 6.1.5 Takeda Pharmaceutical Recent Developments
  7. 6.2 Novartis
  8. 6.2.1 Novartis Company Information
  9. 6.2.2 Novartis Business Overview
  10. 6.2.3 Novartis Drugs for Metabolic Disorders Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Novartis Drugs for Metabolic Disorders Product Portfolio
  12. 6.2.5 Novartis Recent Developments
  13. 6.3 Merck
  14. 6.3.1 Merck Company Information
  15. 6.3.2 Merck Business Overview
  16. 6.3.3 Merck Drugs for Metabolic Disorders Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Merck Drugs for Metabolic Disorders Product Portfolio
  18. 6.3.5 Merck Recent Developments
  19. 6.4 Astra Zeneca
  20. 6.4.1 Astra Zeneca Company Information
  21. 6.4.2 Astra Zeneca Business Overview
  22. 6.4.3 Astra Zeneca Drugs for Metabolic Disorders Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Astra Zeneca Drugs for Metabolic Disorders Product Portfolio
  24. 6.4.5 Astra Zeneca Recent Developments
  25. 6.5 Metsubishi Tanabe Pharma
  26. 6.5.1 Metsubishi Tanabe Pharma Company Information
  27. 6.5.2 Metsubishi Tanabe Pharma Business Overview
  28. 6.5.3 Metsubishi Tanabe Pharma Drugs for Metabolic Disorders Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Metsubishi Tanabe Pharma Drugs for Metabolic Disorders Product Portfolio
  30. 6.5.5 Metsubishi Tanabe Pharma Recent Developments
  31. 6.6 LG Life Science
  32. 6.6.1 LG Life Science Company Information
  33. 6.6.2 LG Life Science Business Overview
  34. 6.6.3 LG Life Science Drugs for Metabolic Disorders Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 LG Life Science Drugs for Metabolic Disorders Product Portfolio
  36. 6.6.5 LG Life Science Recent Developments
  37. 6.7 Kythera
  38. 6.7.1 Kythera Company Information
  39. 6.7.2 Kythera Business Overview
  40. 6.7.3 Kythera Drugs for Metabolic Disorders Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Kythera Drugs for Metabolic Disorders Product Portfolio
  42. 6.7.5 Kythera Recent Developments
  43. 6.8 KOWA
  44. 6.8.1 KOWA Company Information
  45. 6.8.2 KOWA Business Overview
  46. 6.8.3 KOWA Drugs for Metabolic Disorders Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 KOWA Drugs for Metabolic Disorders Product Portfolio
  48. 6.8.5 KOWA Recent Developments
  49. 6.9 Fuji yakuhin
  50. 6.9.1 Fuji yakuhin Company Information
  51. 6.9.2 Fuji yakuhin Business Overview
  52. 6.9.3 Fuji yakuhin Drugs for Metabolic Disorders Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Fuji yakuhin Drugs for Metabolic Disorders Product Portfolio
  54. 6.9.5 Fuji yakuhin Recent Developments
  55. 6.10 Boehringer Ingelheim
  56. 6.10.1 Boehringer Ingelheim Company Information
  57. 6.10.2 Boehringer Ingelheim Business Overview
  58. 6.10.3 Boehringer Ingelheim Drugs for Metabolic Disorders Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Boehringer Ingelheim Drugs for Metabolic Disorders Product Portfolio
  60. 6.10.5 Boehringer Ingelheim Recent Developments
7 North America by Country
  1. 7.1 North America Drugs for Metabolic Disorders Sales by Country
  2. 7.1.1 North America Drugs for Metabolic Disorders Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Drugs for Metabolic Disorders Sales by Country (2021-2026)
  4. 7.1.3 North America Drugs for Metabolic Disorders Sales Forecast by Country (2027-2032)
  5. 7.2 North America Drugs for Metabolic Disorders Market Size by Country
  6. 7.2.1 North America Drugs for Metabolic Disorders Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Drugs for Metabolic Disorders Market Size by Country (2021-2026)
  8. 7.2.3 North America Drugs for Metabolic Disorders Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Drugs for Metabolic Disorders Sales by Country
  2. 8.1.1 Europe Drugs for Metabolic Disorders Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Drugs for Metabolic Disorders Sales by Country (2021-2026)
  4. 8.1.3 Europe Drugs for Metabolic Disorders Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Drugs for Metabolic Disorders Market Size by Country
  6. 8.2.1 Europe Drugs for Metabolic Disorders Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Drugs for Metabolic Disorders Market Size by Country (2021-2026)
  8. 8.2.3 Europe Drugs for Metabolic Disorders Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Drugs for Metabolic Disorders Sales by Country
  2. 9.1.1 Asia-Pacific Drugs for Metabolic Disorders Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Drugs for Metabolic Disorders Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Drugs for Metabolic Disorders Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Drugs for Metabolic Disorders Market Size by Country
  6. 9.2.1 Asia-Pacific Drugs for Metabolic Disorders Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Drugs for Metabolic Disorders Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Drugs for Metabolic Disorders Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Drugs for Metabolic Disorders Sales by Country
  2. 10.1.1 South America Drugs for Metabolic Disorders Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Drugs for Metabolic Disorders Sales by Country (2021-2026)
  4. 10.1.3 South America Drugs for Metabolic Disorders Sales Forecast by Country (2027-2032)
  5. 10.2 South America Drugs for Metabolic Disorders Market Size by Country
  6. 10.2.1 South America Drugs for Metabolic Disorders Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Drugs for Metabolic Disorders Market Size by Country (2021-2026)
  8. 10.2.3 South America Drugs for Metabolic Disorders Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Drugs for Metabolic Disorders Sales by Country
  2. 11.1.1 Middle East and Africa Drugs for Metabolic Disorders Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Drugs for Metabolic Disorders Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Drugs for Metabolic Disorders Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Drugs for Metabolic Disorders Market Size by Country
  6. 11.2.1 Middle East and Africa Drugs for Metabolic Disorders Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Drugs for Metabolic Disorders Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Drugs for Metabolic Disorders Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Drugs for Metabolic Disorders Value Chain Analysis
  2. 12.1.1 Drugs for Metabolic Disorders Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Drugs for Metabolic Disorders Production Mode & Process
  7. 12.2 Drugs for Metabolic Disorders Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Drugs for Metabolic Disorders Distributors
  10. 12.2.3 Drugs for Metabolic Disorders Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst